You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

210 Results
Regimen
Cancer Type:
Genitourinary, 
Testis
Intent: Palliative
Jan 2018
Regimen
Cancer Type:
Gynecologic, 
Uterine Sarcoma, 
Sarcoma, 
Uterine
Intent: Palliative
May 2020
Regimen
Cancer Type:
Gastrointestinal, 
Pancreas
Intent: Palliative
Funding:
New Drug Funding Program
    Gemcitabine and Nab-Paclitaxel - Advanced Pancreatic Cancer
Jan 2024
Regimen
Intent: Palliative
May 2020
Regimen
Cancer Type:
Hematologic, 
Multiple Myeloma
Intent: Palliative
Funding:
ODB Limited Use
    lenalidomide - For the maintenance treatment of patients with newly diagnosed multiple myeloma, following ASCT, according to clinical criteria
May 2022
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's High Grade, 
Lymphoma - Non-Hodgkin's Intermediate Grade
Intent: Curative
Funding:
New Drug Funding Program
    Rituximab (Biosimilar IV) and Rituximab SC - Retreatment - Aggressive Histology Lymphoma
ODB - General Benefit
    dexamethasone
New Drug Funding Program
    Rituximab (Biosimilar IV) and Rituximab SC - Retreatment - Aggressive Histology Lymphoma
Jan 2024
Regimen
Cancer Type:
Gynecologic, 
Ovary
Intent: Palliative
Funding:
ODB - General Benefit
    letrozole
Aug 2025
Regimen
Cancer Type:
Genitourinary, 
Testis
Intent: Palliative
May 2019
Regimen
Cancer Type:
Sarcoma, 
Soft Tissue
Intent: Palliative
May 2020
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Hodgkin
Intent: Palliative
May 2019
Regimen
Cancer Type:
Endocrine, 
Thyroid
Intent: Palliative
Funding:
Exceptional Access Program
    lenvatinib - For the treatment of patients with locally recurrent or metastatic, progressive, radioactive-iodine-refractory differentiated thyroid cancer (DTC) according to criteria
Sep 2020
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Hodgkin
Intent: Curative, Palliative
Nov 2017

Pages